Jong Wook Chang
Scientific Tracks Abstracts: J Tissue Sci Eng
H uman umbilical cord blood-derived msenchymal stem cell (hUCB-MSC) has been regarded as a fascinating candidate of stem cell therapy in alzheimer?s disease (AD). Recently, we reported that transplantation of hUCB-MSC reduced amyloid plaques via release of soluble intercellular adhesion molecule-1 in vitro and in vivo. In addition, we observed that a certain secreted proteins of hUCB-MSC stimulate neurogenesis in a transgenic mice model of AD. These data suggested that secreted proteins of hUCB-MSC act simultaneously in microenvironment of AD. Based on these findings, we already finished Phase I clinical trial in Korea. In this presentation, I will briefly introduce our efforts to develop hUCB-MSC therapeutics for AD from the bench to clinical trial.
Chang has completed his Ph.D in 2005 from Gwangju-Institute of Science & Technology (GIST) and postdoctoral studies from Korea-Institute of Science & Technology (KIST). Now, he is the director of research division II in R&D Center of MEDIPOST Co., Ltd which is a leading biopharmaceutical company of cord blood MSC therapeutics in South Korea. He also has been worked as a project manager for phase I clinical trial for AD using hUCB- MSC. He has published more than 13 papers after 2008 in reputed journals regarding stem cells and serving as an editorial board member of World Journal of Stem Cells.
Journal of Tissue Science and Engineering received 807 citations as per Google Scholar report